Human2020-07-28
Substance-use research · CBD
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
The lancet. Psychiatry · PMID 32735782
Phase 2a randomized adaptive trial
- Studied preparation
- Controlled oral CBD preparations compared with matched placebo.
- Population / model
- 82 participants with cannabis use disorder attempting cessation; all received motivational interviewing.
- What was observed
- Some treatment arms met prespecified adaptive endpoint criteria for cannabis-use reduction.
Interpretation limit
Early dose-finding study with a concurrent psychological intervention; it does not support self-treatment with a shop product.
Online publication · Source checked 2026-10-25
Sources, registration and terms
Citation and publication date recorded; peer-review/preprint status not separately classified.
PMC full-text link is recorded; current access and reuse rights are not verified here.
Registry state is a dated sponsor report; it does not confirm current recruitment or establish benefit.
- Results paper for this recorded registration
NCT02044809 registry context · Original NCT02044809
No results tables posted in registry
Status: Completed — sponsor-reported. Registry updated 2018-10-24; source checked 2026-10-25. - Background topic link; this paper is not results of this trial
NCT06107062 registry context · Original NCT06107062
No results tables posted in registry
Status: Recruiting — sponsor-reported. Registry updated 2026-06-12; source checked 2026-10-25.
CBD / cannabidiol · Human study · Registered trial · Primary versus secondary outcome